| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Payments of contingent consideration liabilities | - | - | - | 0 |
| Cash flows from financing activities | -8,558 | -3,968 | -1,258 | 1,650 |
| Effect of exchange rate changes on cash and equivalents | 31 | 39 | 9 | -19 |
| Net change in cash and equivalents | 105 | 943 | -349 | -5,557 |
| Cash and cash equivalents at beginning of period | 5,524 | - | - | - |
| Cash and cash equivalents at end of period | 5,629 | - | - | - |
AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV)